Table 1 Characteristics at baseline and follow-up visits of 29 RA patients reporting hand flare during 1 year of follow-up
Baseline (n = 29) | FV1 (flare visit) (n = 29) | FV2 (n = 29) | FV3 (n = 28) | FV4 (n = 28) | |
|---|---|---|---|---|---|
No. reporting flare | 0/29 | 29/29 | 22/29 | 3/27 | 6/27 |
Age, years | 64.8 (9.7) | NA | NA | NA | NA |
Female/male (%) | 20/9 (69/31) | NA | NA | NA | NA |
Disease duration, years | 10.3 (5.5) [2–21] | NA | NA | NA | NA |
Anti-CCP positive (%) | 27 (93) | NA | NA | NA | NA |
IgM RF positive (%) | 26 (90) | NA | NA | NA | NA |
DAS28CRP | 2.0 (0.7) [1.2–3.1] | 3.5 (1.0)*** [1.2–5.3] | 3.0 (1.2)*** [1.2–6.0] | 2.4 (0.9) [1.2–4.9] | 2.6 (1.0)* [1.2–4.9] |
CRP (mg/l) | 5.7 (8.6) [0–33] | 10.1 (12.7)*** [0.4–48] | 6.8 (9.2) [0–44] | 6.1 (6.9) [0.4–23] | 6.8 (11.4) [0.4–56] |
SJC28 | 0 (0) [0–0] | 1.5 (1.0)*** [0–4] | 1.0 (1.4)*** [0–5] | 0.2 (0.5) [0–2] | 0.4 (0.7)** [0–3] |
TJC28 | 0.8 (1.5) [0–7] | 4.0 (3.5)*** [0–12] | 3.8 (4.9)*** [0–21] | 1.6 (2.0) [0–8] | 1.9 (2.1)** [0–7] |
EGA (VAS) | 4.1 (3.2) [0–11] | 16.2 (13.1)*** [2–74] | 11 (9.9)*** [0–47] | 5.8 (5.8) [0–27] | 6.5 (5.8) [0–26] |
PROs | |||||
Pain (VAS) | 16.7 (18.4) [0–71] | 43.2 (22.8)*** [0–74] | 36.4 (26.7)** [0–98] | 24.2 (23.7) [0–96] | 25.8 (22.9) [0–74] |
PGA (VAS) | 22.1 (23.1) [0–84] | 43.4 (26.2)*** [0–85] | 37.1 (26.2)** [0–98] | 26.3 (24.3) [0–93] | 26.6 (26.0) [0–80] |
Patient-reported TJC28 | 1 (1.9) [0–8] | 4.0 (3.0)*** [1–11] | 2.5 (3.5)* [0–14] | 1.4 (2.6) [0–13] | 1.8 (2.8) [0–12] |
Patient-reported SJC28 | 0 (0) [0–0] | 2.8 (2.9)*** [1–11] | 1.9 (3.1)*** [0–12] | 0.7 (1.8)** [0–8] | 1 (2.1)** [0–10] |
HAQ | 0.4 (0.4) [0–1.5] | 0.6 (0.5)*** [0–1.5] | 0.5 (0.5) [0–1.8] | 0.4 (0.5) [0–1.9] | 0.5 (0.5) [0–1.9] |
Patient-reported flare characteristics | |||||
RA-FQ (0–50) | 10.1 (9.6) [0–33] | 22.9 (12.7)*** [1–49] | 15 (10.7) [1–37] | 9.5 (8.6) [0–35] | 10.5 (9.9) [0–38] |
Flare severitya (0–10) | NA | 4.8 (2.7) [1–10] | 2.67 (2.4)*** [0–8] | 1.25 (2.3)** [0–9] | 1.45 (2.3)** [0–7] |
Flare duration (n) | |||||
1–3 days | NA | 18 | 4 | 1 | 4 |
4–7 days | NA | 8 | 10 | 0 | 0 |
8–14 days | NA | 2 | 0 | 0 | 0 |
> 14 days | NA | 1 | 4 | 2 | 2 |
MRI | |||||
Synovitis | 10.3 (4.0) [0–17.5] | 12.7 (3.1)*** [7–19] | 11.9 (3.2)** [6–19] | 11.0 (3.7) [3–18.5] | 11.5 (3.6) [4.5–20] |
Tenosynovitis | 6.4 (4.7) [0–17.5] | 9.3 (5.8)*** [1–20.5] | 8.1 (4.9)** [1–19.5] | 7.9 (5.2)** [0–20.5] | 8.2 (4.8)** [0–20.5] |
BME | 2.6 (4.8) [0–22.5] | 2.6 (3.1) [0–11] | 2.9 (3.6)** [0–11.5] | 2.9 (3.5)** [0–12] | 2.9 (3.5)* [0–11.5] |
No. (%) with synovitis sum score ≥ 1 | 28 (97) | 29 (100) | 29 (100) | 26 (100) | 26 (100) |
No. (%) with tenosynovitis sum score ≥ 1 | 28 (97) | 29 (100) | 29 (100) | 25 (96) | 26 (100) |
No. (%) with BME ≥ 1 | 14 (48) | 20 (69) | 18 (62) | 18 (64) | 17 (61) |
US | |||||
Synovitis (GLOESS) | 8.3 (5.4) [0–23] | 11.3 (5.3)* [3–25] | 10.6 (5.0)* [3–23] | 9.7 (5.0) [3–23] | 10.04 (5.1) [3–23] |
Tenosynovitis | 3.5 (4.6) [0–14] | 6.3 (6.2)*** [0–19] | 5.9 (5.9)** [0–24] | 4.4 (5.0) [0–15] | 4.6 (5.0) [0–15] |
No.(%) with GLOESS ≥ 1 | 28 (97) | 29 (100) | 29 (100) | 28 (100) | 28 (100) |
No.(%) with tenosynovitis sum score ≥ 1 | 18 (62) | 20 (69) | 23 (79) | 19 (68) | 19 (68) |